DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) presents the protocol and rationale for ReMEDy2, a pivotal trial in patients suffering from acute ischemic stroke. The company announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference.

Positive

• DiaMedica is focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, indicating a potential breakthrough in stroke treatment.
• The presentation at the American Heart Association 2024 International Stroke Conference demonstrates the company's commitment to advancing its clinical-stage biopharmaceutical development.
• The planned pivotal phase 2/3 trial of DM199 in AIS patients shows a significant step towards potential regulatory approval and commercialization.
• The announcement at a prestigious conference like the American Heart Association 2024 International Stroke Conference indicates the company's efforts to gain visibility and recognition within the medical and scientific community.

Negative

• None.

DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024. For information about the event, visit: https://professional.heart.org/en/meetings/international-stroke-conference.

The DiaMedica poster is:

Poster Title: “Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study To Evaluate The Safety And Efficacy Of Dm199 For The Treatment Of Acute Ischemic Stroke (ReMEDy2 Trial)”

The poster will be located in Poster Hall 5-6 (Poster Board CTP36). On Thursday February 8, 2024, from 7:00 PM – 07:30 PM. Dr. Scott Kasner, ReMEDy2 trial National Principal Investigator, will be present to answer questions about the poster. Following the session, a reprint of the poster will be accessible from DiaMedica’s website at: https://www.diamedica.com/investors/events-presentations.

DiaMedica will also be exhibiting at the conference located in the main hall at booth 1021.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240129496878/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: (508) 444-6790

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

What is the ticker symbol for DiaMedica Therapeutics Inc.?

The ticker symbol for DiaMedica Therapeutics Inc. is DMAC.

What is the focus of DiaMedica Therapeutics Inc. in developing recombinant KLK1 (DM199)?

DiaMedica Therapeutics Inc. is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS).

Where was the poster presentation of the design and rationale for ReMEDy2 announced?

The poster presentation of the design and rationale for ReMEDy2 was announced at the American Heart Association 2024 International Stroke Conference.

What is the significance of the ReMEDy2 trial in AIS patients for DiaMedica Therapeutics Inc.?

The ReMEDy2 trial in AIS patients is a pivotal phase 2/3 trial of DM199, indicating a significant step towards potential regulatory approval and commercialization for the company.